Compounded tirzepatide vials recalled over sterility concerns
Published
North Carolina's Apothecary Pharma recalled 22 lots of compounded tirzepatide, a GLP-1 weight-loss drug, plus one lot of NAD+ injection, because sterility can't be assured. FDA rates it Class II and no illnesses have been reported. Check your vial and call your prescriber.
Source: FOX 5 New York
This is a plain-language summary. Read the original source for full details.